3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

NCT01563354 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Carcinoma of the Lung and Thymus

Interventions

DRUG: Pasireotide LAR
DRUG: Everolimus
DRUG: Pasireotide LAR and Everolimus Combination

Sponsor

Novartis Pharmaceuticals